[go: up one dir, main page]

CO6470799A2 - Composición farmacéutica oral auto-microemulsificante de un farmaco hidrofílico y método de preparación de ésta - Google Patents

Composición farmacéutica oral auto-microemulsificante de un farmaco hidrofílico y método de preparación de ésta

Info

Publication number
CO6470799A2
CO6470799A2 CO11159571A CO11159571A CO6470799A2 CO 6470799 A2 CO6470799 A2 CO 6470799A2 CO 11159571 A CO11159571 A CO 11159571A CO 11159571 A CO11159571 A CO 11159571A CO 6470799 A2 CO6470799 A2 CO 6470799A2
Authority
CO
Colombia
Prior art keywords
oral
preparation
pharmaceutical composition
hydrophyl
microemulsifying
Prior art date
Application number
CO11159571A
Other languages
English (en)
Inventor
Chang-Shan Hsu
Wei-Hua Hao
Jong-Jing Wang
Tsung-Hsing Lin
Original Assignee
Innopharmax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42992661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6470799(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innopharmax Inc filed Critical Innopharmax Inc
Publication of CO6470799A2 publication Critical patent/CO6470799A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulga una composición farmacéutica auto-microemulsificante de un fármaco hidrofílico o su sal aceptable farmacéuticamente y el método de preparación de esta. La composición comprende un fármaco hidrofílico tal como bendamustina o gemcitabina, solvente, surfactante y vehículo hidrofílico, y tiene buena biodisponibilidad y estabilidad. Dicho vehículo hidrofílico es compatible con la solución del fármaco y el surfactante.
CO11159571A 2009-04-27 2011-11-22 Composición farmacéutica oral auto-microemulsificante de un farmaco hidrofílico y método de preparación de ésta CO6470799A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17290109P 2009-04-27 2009-04-27

Publications (1)

Publication Number Publication Date
CO6470799A2 true CO6470799A2 (es) 2012-06-29

Family

ID=42992661

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11159571A CO6470799A2 (es) 2009-04-27 2011-11-22 Composición farmacéutica oral auto-microemulsificante de un farmaco hidrofílico y método de preparación de ésta

Country Status (20)

Country Link
US (3) US20100273730A1 (es)
EP (2) EP2425818A4 (es)
JP (1) JP5753157B2 (es)
KR (1) KR101759750B1 (es)
CN (1) CN102427803B (es)
AU (1) AU2010242461B2 (es)
BR (1) BRPI1011764A2 (es)
CA (1) CA2760039C (es)
CO (1) CO6470799A2 (es)
ES (1) ES2831037T3 (es)
IL (1) IL215988A (es)
MX (1) MX349014B (es)
MY (1) MY174001A (es)
NZ (1) NZ596657A (es)
RU (1) RU2532362C2 (es)
SG (1) SG175808A1 (es)
TW (1) TWI461212B (es)
UA (1) UA105042C2 (es)
WO (1) WO2010124525A1 (es)
ZA (1) ZA201108686B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
ES2690257T3 (es) * 2010-06-02 2018-11-20 Astellas Deutschland Gmbh Formas de dosificación oral de bendamustina
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6250628B2 (ja) 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
PL3533447T3 (pl) * 2012-03-20 2023-07-17 Eagle Pharmaceuticals, Inc. Ciekłe kompozycje bendamustyny do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2922099C (en) 2013-08-27 2022-11-29 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
IN2014CH00151A (es) * 2014-01-13 2015-07-17 Hetero Research Foundation
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2951284A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
WO2016071756A1 (en) 2014-11-04 2016-05-12 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10335405B1 (en) * 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CA3026144A1 (en) * 2016-06-02 2017-12-07 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US20200206139A1 (en) * 2017-09-11 2020-07-02 Board Of Regents, The University Of Texas System Compositions for the improved delivery of drugs
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
US11752165B2 (en) * 2020-04-13 2023-09-12 US Nano Food & Drug, Inc Basic chemotherapeutic intratumour injection formulation
CN112006986A (zh) * 2020-08-07 2020-12-01 厦门大学 一种维生素e琥珀酸酯聚乙二醇纳米胶束及其制备方法和应用
CN114397381A (zh) * 2021-12-17 2022-04-26 南京农业大学 一种沼液中阿莫西林的提取及含量检测方法
CN115737558B (zh) * 2022-11-22 2025-08-15 中南大学湘雅医院 一种含有拉莫三嗪的自微乳组合物及其应用
US20250195418A1 (en) * 2023-08-21 2025-06-19 Cmpd Licensing, Llc Topical administration to the oral cavity
WO2025238457A1 (en) * 2024-05-13 2025-11-20 Nanda Gargi An oral self-micro-emulsifying pharmaceutical composition of a hydrophilic drug

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE317397T1 (de) * 1993-11-17 2006-02-15 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
NZ505163A (en) * 1997-12-26 2002-11-26 Yamanouchi Pharma Co Ltd Sustained release medicinal compositions comprising an ionic compound with an opposite charge to the ionic active substance
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US7217735B1 (en) * 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7309696B2 (en) * 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
IL159119A0 (en) * 2001-06-15 2004-05-12 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
EE200400024A (et) * 2001-06-21 2004-06-15 Pfizer Products Inc. Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
US7053076B2 (en) * 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
DE10306724A1 (de) * 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
EA008244B1 (ru) * 2002-05-03 2007-04-27 Янссен Фармацевтика Н.В. Полимерные микроэмульсии
WO2004017944A1 (en) 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
CN1593405A (zh) * 2004-07-09 2005-03-16 沈阳药科大学 一种氟康唑液体型组方及其制剂
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US20090169610A1 (en) 2006-02-03 2009-07-02 Noboru Yamazaki Liposome Preparation
CA2645080A1 (en) * 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
WO2009032246A2 (en) * 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs

Also Published As

Publication number Publication date
EP3045165A3 (en) 2016-09-21
BRPI1011764A2 (pt) 2016-03-29
MX2011011374A (es) 2012-02-08
TW201041597A (en) 2010-12-01
AU2010242461A1 (en) 2011-12-15
EP2425818A1 (en) 2012-03-07
KR101759750B1 (ko) 2017-07-31
HK1165701A1 (en) 2012-10-12
CN102427803B (zh) 2015-06-10
ZA201108686B (en) 2012-08-29
IL215988A0 (en) 2012-01-31
US20150196537A1 (en) 2015-07-16
KR20120015330A (ko) 2012-02-21
TWI461212B (zh) 2014-11-21
AU2010242461B2 (en) 2016-05-19
JP5753157B2 (ja) 2015-07-22
US20100273730A1 (en) 2010-10-28
MX349014B (es) 2017-07-06
CA2760039C (en) 2017-05-16
IL215988A (en) 2016-12-29
RU2532362C2 (ru) 2014-11-10
MY174001A (en) 2020-03-03
CA2760039A1 (en) 2010-11-04
EP3045165B1 (en) 2020-09-23
NZ596657A (en) 2014-01-31
EP3045165A2 (en) 2016-07-20
CN102427803A (zh) 2012-04-25
SG175808A1 (en) 2011-12-29
UA105042C2 (uk) 2014-04-10
EP2425818A4 (en) 2012-10-24
US20190275006A1 (en) 2019-09-12
JP2012524820A (ja) 2012-10-18
WO2010124525A1 (zh) 2010-11-04
ES2831037T3 (es) 2021-06-07
RU2011148140A (ru) 2013-06-10

Similar Documents

Publication Publication Date Title
CO6470799A2 (es) Composición farmacéutica oral auto-microemulsificante de un farmaco hidrofílico y método de preparación de ésta
DOP2020000062A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
NI201200086A (es) Composición farmacéutica que comprende un agonista de glp - 1 y metionina
NI201200017A (es) Formulación farmacéutica
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CL2013000378A1 (es) Combinacion farmaceutica que comprende un farmaco antipsicotico atipico, tal como risperidona y olanzapina, entre otros, y un compuesto derivado de piperazina-fenil-metanona, antagonista del receptor de glyt1; método de tratamiento; y su uso para el tratamiento de sintomas positivos y negativos de la esquizofrenia.
GT200900328A (es) Derivados de bencimidazol
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
LTPA2019508I1 (lt) Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui
BRPI0910758A2 (pt) composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
AR059357A1 (es) Formulaciones farmaceuticas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
BR112013013903A2 (pt) preparação farmacêutica aquosa estável pronta para uso de cetrorelix para administração parenteral, processo para a fabricação de uma preparação farmacêutica aquosa estável pronta para uso de cetrorelix para uso de cetrorelix para administração parenteral
MX2012003001A (es) Proceso para la produccion de intermediarios de artemisina.
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
CO2019005955A2 (es) Preparación farmacéutica y método para su fabricación
MX2012010707A (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.
AR105503A1 (es) Concentrado que contiene alprostadil

Legal Events

Date Code Title Description
FC Application refused